[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intracranial-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intracranial-tumor":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100597838","phase-1-aby-029-glioma-trial-100597838",false,"NCT07063693","ABY-029 Glioma Trial","Phase 1 Trial of ABY-029 Fluorescence in Patients With High-Grade Glioma","Inclusion Criteria:\n\n1. Clinical diagnosis of presumed high-grade glioma, based on image data.\n2. Tumor judged to be suitable and planned for open cranial resection.\n3. Valid informed consent by participant.\n4. Age ≥ 18 years old.\n5. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Prisoners\n2. Individuals who are pregnant or breast feeding.\n3. Participants on any experimental or approved anti-EGFR targeted therapies\n4. Elevated kidney or liver function tests (levels greater than 2.5 times the normal limit) from laboratory tests conducted as part of standard-of-care screening of prospective surgical participants no earlier than 30 days prior to surgery.\n5. Any condition which, in the opinion of the clinical investigator, contraindicates research participation.","ALL","18 Years",{"count":19,"type":20},33,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The purposes of the research trial are to study the safety of ABY-029 and to understand how much of the drug is needed to reach brain tumors so it can be visualized best by surgeons. Investigators will do this by comparing two groups of participants that receive different, very small amounts of ABY-029. Investigators will use an imaging system during surgery to record the amount of ABY-029 in the participant's tumor and in the surrounding tissue.",[26],"Intracranial Tumor",[28,29,30,31],"ABY-029","Affibody","Molecular Fluorescence-Guided Surgery","Epidermal Growth Factor Receptor (EGFR)","RECRUITING","2026-03-07",{"date":35,"type":36},"2026-03-10","ACTUAL",{"date":38,"type":36},"2026-02-17",{"date":40,"type":20},"2028-12-31",{"name":42,"class":43},"Dartmouth-Hitchcock Medical Center","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":44},"100543932","99mtc-cndg-spectct-in-brain-tumors-100543932","NCT06362304","99mTc-CNDG SPECT\u002FCT in Brain Tumors","Application of 99mTc-CNDG SPECT\u002FCT Imaging in the Diagnosis of Brain Tumors","Inclusion Criteria:\n\n* Patients with clinical diagnosis of brain tumor;\n* Be at least 18 years old;\n* The final pathological results could be obtained by surgery or biopsy;\n* Informed consent and the ability to be followed up;\n* Those who did not meet the exclusion criteria.\n\nExclusion Criteria:\n\n* Insulin-dependent diabetes mellitus or fasting blood glucose \\>7 mmol\u002FL before 99mTc-CNDG injection;\n* Severe liver or kidney disease (serum creatinine level \\>3.0mg\u002FdL or any liver enzyme level ≥ 5 times the upper limit of normal);\n* Severe hypersensitivity or hypersensitivity to radiocontrast agents;\n* Claustrophobia (inability to undergo SPECT\u002FCT or PET\u002FCT scans);\n* Patients receiving radiotherapy and chemotherapy;\n* Being pregnant or breastfeeding.",{"count":53,"type":20},30,[55],"NA","The goal of this clinical trial is to evaluate the value of 99mTc-CNDG for diagnosis of brain tumors by comparing it with 18F-FDG-PET. The main questions it aims to answer are:\n\n1. What is the diagnostic consistency between 99mTc-CNDG and 18F-FDG?\n2. What is the correlation between the SUVmax value of 99mTc-CNDG and tumor type?\n\nParticipants will:\n\nReceive18F-FDG-PET and 99mTc-CNDG examination within 2 weeks before surgery. Obtain pathological diagnosis by surgery or biopsy as the gold standard.",[26],"2024-11-21",{"date":60,"type":36},"2024-11-25",{"date":62,"type":36},"2024-04-20",{"date":64,"type":20},"2025-04",{"name":66,"class":43},"Peking Union Medical College Hospital",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100559087","evaluation-of-postoperative-intracranial-pressure-in-patients-undergoing-intracranial-tumor-surgery-100559087","NCT06559566","Evaluation of Postoperative Intracranial Pressure in Patients Undergoing Intracranial Tumor Surgery","Comparison of Two Methods Used to Asses Postoperative Intracranial Pressure in Patients Undergoing Intracranial Tumor Surgery","Inclusion Criteria:\n\n* Patients over 18 -65 years\n* Brain malignant neoplasm tumor\n* Brain benign neoplasm supratentorial\n* Brain benign neoplasm infratentorial information\n\nExclusion Criteria:\n\n* Patients who cannot provide adequate image quality in ocular ultrasonography\n* Who are unconscious or have a Glasgow coma scale of less than 15\n* Pseudotumor cerebri\n* Optic nerve arachnoid cyst\n* Patients with open injuries involving the eyelid and surrounding area\n* Optic nerve malignant neoplasm\n* Injury of the optic nerve and its pathways\n* Systemic Lupus Erythematosis,\n* Scleroderma\n* Multiple Sclerosis, sarcoidosis\n* Thyrotoxicosis (hyperthyroidism)","65 Years",{"count":76,"type":20},50,[55],"Ultrasonography(USG)-guided optic nerve sheath diameter measurement and its correlation with brain computed tomography in the evaluation of intracranial pressure in patients who underwent intracranial brain tumor surgery.",[80,81,82],"INTRACRANIAL TUMOR","INTRACRANIAL PRESSURE","OPTIC NERVE",[82,81,80,84,85],"INTRACRANIAL TUMOR SURGERY","Intracranial Pressure Change","NOT_YET_RECRUITING","2024-08-15",{"date":89,"type":36},"2024-08-19",{"date":91,"type":20},"2024-09-15",{"date":93,"type":20},"2025-05-01",{"name":95,"class":96},"Sezen Kumaş Solak","OTHER_GOV"]